Thursday, October 15, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 27, 2026

Waste-to-Hydrogen Industry Research Report 2025: An $825+ Mn Market by 2030, Driven by Advancements in Gasification and Pyrolysis Technologies and Focus on Industrial Decarbonization

View original at finance.yahoo.com
Waste-to-Hydrogen Industry Research Report 2025: An $825+ Mn Market by 2030, Driven by Advancements in Gasification and Pyrolysis Technologies and Focus on Industrial Decarbonization Company Logo The Waste-to-Hydrogen Market, valued at USD 825.4 million in 2025, is expected to reach USD 50.9 million by 2035, exhibiting…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The Waste-to-Hydrogen Market is projected to reach USD 825.4 million by 2035

    80% confidence

  • Innovations in carbon capture and AI optimize waste-to-hydrogen operations

    80% confidence

  • Chemical production is expected to dominate the waste-to-hydrogen market over the forecast period

    80% confidence

  • The Waste-to-Hydrogen Market will grow at a CAGR of 32.12% from 2025 to 2035

    80% confidence

  • The chemical production segment is projected to reach $275.4 million by 2035

    80% confidence

  • The chemical production segment was valued at $12.8 million in 2024

    80% confidence

  • The Waste-to-Hydrogen Market was valued at USD 50.9 Million in 2025

    80% confidence

  • The chemical production segment will exhibit a robust CAGR of 32.72%

    80% confidence

  • The waste-to-hydrogen market transforms waste into clean hydrogen fuel, aiding global decarbonization

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com
Waste-to-Hydrogen Industry Research Report 2025: An $825+ Mn Market by 2030, Driven by Advancements in Gasification and Pyrolysis Technologies and Focus on Industrial Decarbonization — Source | Via News | Via News